Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 378

1.

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.

Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC.

Clin Trials. 2005;2(6):509-18.

PMID:
16422311
[PubMed - indexed for MEDLINE]
2.

A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?

Clarke CE.

Mov Disord. 2004 May;19(5):491-8. Review.

PMID:
15133811
[PubMed - indexed for MEDLINE]
3.

A responsive outcome for Parkinson's disease neuroprotection futility studies.

Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators.

Ann Neurol. 2005 Feb;57(2):197-203.

PMID:
15668964
[PubMed - indexed for MEDLINE]
4.

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.

Chan PL, Nutt JG, Holford NH.

Pharm Res. 2007 Apr;24(4):791-802. Epub 2007 Feb 17.

PMID:
17308968
[PubMed - indexed for MEDLINE]
5.

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.

Rascol O.

Neurology. 2009 Feb 17;72(7 Suppl):S51-8. doi: 10.1212/WNL.0b013e318199049e. Review.

PMID:
19221315
[PubMed - indexed for MEDLINE]
6.

Functional decline in Parkinson disease.

Jankovic J, Kapadia AS.

Arch Neurol. 2001 Oct;58(10):1611-5.

PMID:
11594919
[PubMed - indexed for MEDLINE]
7.

Minimal clinically important change on the unified Parkinson's disease rating scale.

Schrag A, Sampaio C, Counsell N, Poewe W.

Mov Disord. 2006 Aug;21(8):1200-7.

PMID:
16673410
[PubMed - indexed for MEDLINE]
8.

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

Clarke CE.

Mov Disord. 2008 Apr 30;23(6):784-9. doi: 10.1002/mds.21918.

PMID:
18175348
[PubMed - indexed for MEDLINE]
9.

Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating.

Sch├╝pbach WM, Corvol JC, Czernecki V, Djebara MB, Golmard JL, Agid Y, Hartmann A.

J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):20-5. doi: 10.1136/jnnp.2008.159699. Epub 2009 Jul 20.

PMID:
19622523
[PubMed - indexed for MEDLINE]
10.

Progress in neuroprotection in Parkinson's disease.

Schapira AH.

Eur J Neurol. 2008 Apr;15 Suppl 1:5-13. doi: 10.1111/j.1468-1331.2008.02055.x. Review.

PMID:
18353131
[PubMed - indexed for MEDLINE]
11.

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.

Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.

Clin Ther. 2009 Jan;31(1):89-98. doi: 10.1016/j.clinthera.2009.01.012. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
19243709
[PubMed - indexed for MEDLINE]
12.

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.

Mov Disord. 2007 Dec;22(16):2409-17.

PMID:
17894339
[PubMed - indexed for MEDLINE]
13.

Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.

Tsai ST, Lin SH, Chou YC, Pan YH, Hung HY, Li CW, Lin SZ, Chen SY.

Stereotact Funct Neurosurg. 2009;87(4):241-8. doi: 10.1159/000225977. Epub 2009 Jun 26.

PMID:
19556833
[PubMed - indexed for MEDLINE]
14.

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I; Parkinson Study Group.

J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):281-311. Epub 2006 Apr 20.

PMID:
16625427
[PubMed - indexed for MEDLINE]
15.

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; TEMPO Open-label Study Group.

Mov Disord. 2009 Mar 15;24(4):564-73. doi: 10.1002/mds.22402.

PMID:
19086083
[PubMed - indexed for MEDLINE]
16.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
[PubMed - indexed for MEDLINE]
17.

Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.

Marras C, Lang AE.

Expert Rev Neurother. 2004 Nov;4(6):985-93. Review.

PMID:
15853525
[PubMed - indexed for MEDLINE]
18.

Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale-III in Parkinson's disease.

Haaxma CA, Bloem BR, Borm GF, Horstink MW.

Mov Disord. 2008 Sep 15;23(12):1707-17. doi: 10.1002/mds.22197.

PMID:
18649395
[PubMed - indexed for MEDLINE]
19.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.

PMID:
21287602
[PubMed - indexed for MEDLINE]
20.

Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

Chen JJ, Swope DM, Dashtipour K.

Clin Ther. 2007 Sep;29(9):1825-49. Review.

PMID:
18035186
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk